Cat. No.: HY-17021

Esomeprazole

(Synonyms: (S)-Omeprazole; (-)-Omeprazole)

3 Cited Publications

Avis client

Based on 3 publication(s) in Google Scholar

Esomeprazole ((S)-Omeprazole) is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H⁺, K⁺-ATPase in gastric parietal cells. Esomeprazole has the potential for symptomatic gastroesophageal reflux disease research.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.32%
CAS No.: 119141-88-7
Formule: C₁₇H₁₉N₃O₃S
Masse moléculaire:345.42

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Esomeprazole Chemical Structure

CAS No.: 119141-88-7

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (3)
Solvant et solubilité
- In Vitro
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

H⁺, K⁺-ATPase^[1]^[2]

Cellular Effect

Cell Line	Type	Value	Description	References
BXPC-3	IC₅₀	14.8 μM Compound: omeprazole	Inhibition of survival of human BxPC3 cells after 10 to 14 days by crystal violet staining-based colony formation assay Inhibition of survival of human BxPC3 cells after 10 to 14 days by crystal violet staining-based colony formation assay	[PMID: 25513712]
HEK293	EC₅₀	14000 nM Compound: 1a	Agonist activity at recombinant BRS-3 receptor expressed in baculovirus-transduced HEK293 cells assessed as intracellular calcium mobilization by FLIPR assay Agonist activity at recombinant BRS-3 receptor expressed in baculovirus-transduced HEK293 cells assessed as intracellular calcium mobilization by FLIPR assay	[PMID: 18818070]
HEK-293T	IC₅₀	25 μM Compound: Omeprazole	Inhibition of recombinant human C-MYC/DDK-tagged ENGase expressed in HEK293T cells using heat inactivated bovine ribonuclease B as substrate pretreated for 15 mins followed by substrate addition after 90 mins by SDS-PAGE analysis Inhibition of recombinant human C-MYC/DDK-tagged ENGase expressed in HEK293T cells using heat inactivated bovine ribonuclease B as substrate pretreated for 15 mins followed by substrate addition after 90 mins by SDS-PAGE analysis	[PMID: 28512024]
HUVEC	GI₅₀	>100 μM Compound: Esomeprazole	Cytotoxicity against HUVEC cells Cytotoxicity against HUVEC cells	[PMID: 31923859]
K562	GI₅₀	>100 μM Compound: Esomeprazole	Antiproliferative activity against human K562 cells harboring MLL1 Antiproliferative activity against human K562 cells harboring MLL1	[PMID: 31923859]
L02	GI₅₀	>100 μM Compound: Esomeprazole	Cytotoxicity against human L02 cells Cytotoxicity against human L02 cells	[PMID: 31923859]
MOLM-13	GI₅₀	32 μM Compound: Esomeprazole	Antiproliferative activity against human MOLM-13 cells harboring MLL1-AF9 Antiproliferative activity against human MOLM-13 cells harboring MLL1-AF9	[PMID: 31923859]
MV4-11	GI₅₀	47.6 μM Compound: Esomeprazole	Antiproliferative activity against human MV4-11 cells harboring MLL1-AF4 Antiproliferative activity against human MV4-11 cells harboring MLL1-AF4	[PMID: 31923859]
Vero C1008	CC₅₀	>40 μM Compound: Omeprazole	Cytotoxicity (CC50) determination in Vero E6 cells measured by fluorescence (OD590nm) Cytotoxicity (CC50) determination in Vero E6 cells measured by fluorescence (OD590nm)	10.1101/2020.04.03.023846
Vero C1008	EC₅₀	17.06 μM Compound: Omeprazole	Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days Antiviral efficacy against SARS-CoV-2 (strain BavPat1) in Vero E6 cells assessed by inhibition of viral RNA replication measured by RT-PCR after 2 days	10.1101/2020.04.03.023846

In Vitro

Esomeprazole (25-100 µM; 20 hours; MDA-MB-468 cells) treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

MDA-MB-468 cells
Concentration:

25 µM, 50 µM, 75 µM, 100 µM
Incubation Time:

20 hours
Result:

Suppressed growth of triple-negative breast cancer cell in vitro in a dose-dependent manner.

In Vivo

Esomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6J mice (8-weeks old, 25-30 g) treated with cotton smoke-induced lung injury^[2]
Dosage:

30 mg/kg, 300 mg/kg
Administration:

Oral gavage; daily; for 19 or 11 days
Result:

Significantly inhibited the progression of fibrosis throughout the lungs of the animals.

Chemical Information

CAS No. 119141-88-7
Appearance Solid
Masse moléculaire 345.42
Formule C₁₇H₁₉N₃O₃S
Color White to light brown
SMILES

O=[S@](C1=NC2=CC=C(OC)C=C2N1)CC3=NC=C(C)C(OC)=C3C
Synonyms

(S)-Omeprazole; (-)-Omeprazole
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (3)

All

Sort by:

Journal Impact Factor

Chem Eng J

2024 Dec 1.
Int Immunopharmacol

Inhibition of iron ion accumulation alleviates polystyrene nanoplastics-induced pulmonary fibroblast proliferation and activation. [Abstract]

2025 Aug 13:164:115367. PMID: 40811949
SSRN

2025 Aug 20.

Solvant et solubilité

In Vitro:

DMSO : ≥ 100 mg/mL (289.50 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.8950 mL

14.4751 mL

28.9503 mL

5 mM

0.5790 mL

2.8950 mL

5.7901 mL

10 mM

0.2895 mL

1.4475 mL

2.8950 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (274 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Wayne Goh, et al. Use of proton pump inhibitors as adjunct treatment for triple-negative breast cancers. An introductory study. J Pharm Pharm Sci. 2014;17(3):439-46. [Content Brief]

[2]. Christina Nelson, et al. Therapeutic Efficacy of Esomeprazole in Cotton Smoke-Induced Lung Injury Model. Front Pharmacol. 2017 Jan 26;8:16. [Content Brief]

[3]. Thomas J Johnson, et al. Esomeprazole: a clinical review. Am J Health Syst Pharm. 2002 Jul 15;59(14):1333-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.8950 mL	14.4751 mL	28.9503 mL	72.3757 mL
	5 mM	0.5790 mL	2.8950 mL	5.7901 mL	14.4751 mL
	10 mM	0.2895 mL	1.4475 mL	2.8950 mL	7.2376 mL
	15 mM	0.1930 mL	0.9650 mL	1.9300 mL	4.8250 mL
	20 mM	0.1448 mL	0.7238 mL	1.4475 mL	3.6188 mL
	25 mM	0.1158 mL	0.5790 mL	1.1580 mL	2.8950 mL
	30 mM	0.0965 mL	0.4825 mL	0.9650 mL	2.4125 mL
	40 mM	0.0724 mL	0.3619 mL	0.7238 mL	1.8094 mL
	50 mM	0.0579 mL	0.2895 mL	0.5790 mL	1.4475 mL
	60 mM	0.0483 mL	0.2413 mL	0.4825 mL	1.2063 mL
	80 mM	0.0362 mL	0.1809 mL	0.3619 mL	0.9047 mL
	100 mM	0.0290 mL	0.1448 mL	0.2895 mL	0.7238 mL

Keywords

Esomeprazole

3 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Esomeprazole

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Membrane Transporter/Ion Channel Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Antibacterial Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Breast Cancer Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

EMA-Approved Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Non-steroidal Anti-Inflammatory Compound Library

Heterocyclic Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Classic FDA-Approved Drug Library

Drug Fragment Library

MCE Kinase Hinge Binder Fragment Library

Publications Citing Use of MedChemExpress (MCE) Esomeprazole

Activité biologique

Chemical Information

Publications (3)

Solvant et solubilité

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Esomeprazole Related Classifications

HY-17021 Related Classifications